EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, is now recruiting
Cure Parkinson’s is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson’s in the UK – EJS ACT-PD – is underway, with recruitment now open to people with Parkinson’s. The Edmond J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD)...
Learn more
Our two newest pre-clinical research projects
Cure Parkinson’s is pleased to announce the funding for two new projects as part of our annual iLCT Pipeline Research Acceleration Grant Programme.
STEM-PD, a cell-replacement trial for Parkinson’s, releases latest update
The STEM-PD trial has recently released an update, which indicates the team is proceeding to the next trial stage based on early positive safety data.
Clinical trial of lithium in Parkinson’s set to begin
We are delighted to announce funding for an upcoming phase1b clinical trial to investigate whether lithium, a drug currently used to treat mood disorders, could be repurposed to slow down Parkinson’s.
Accelerating Parkinson’s drug development: The International Linked Clinical Trials initiative
In 2012, Cure Parkinson’s joined forces with Van Andel Institute (VAI) to hold the first international Linked Clinical Trials (iLCT) meeting in Grand Rapids, Michigan. The Committee has since met annually to evaluate and prioritise drugs for clinical trial in Parkinson’s, a review of which has now been published in the Journal of Parkinson’s Disease.
Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the…